CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Lumee Oxygen Platformdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04204993
NCT04204993N/ACompleted

Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)

Imperial College London·interventional·Posted Dec 19, 2019·Updated Aug 21, 2023

In Brief

A clinical study evaluating Lumee Oxygen Platform for Influenza A H3N2. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The aim of the study is to investigate disease in volunteers deliberately infected with influenza A(H3N2), including biological markers of inflammation and immune response, and changes in physiological parameters including heart rate, respiratory rate, physical activity, oxygen saturation and electrocardiographic data during the onset of influenza infection. Ultimately, this may lead to prediction of symptomatic disease at an earlier stage to allow more effective interventions. The experimental medicine study design will involve human influenza infection challenge, whereby volunteers will be inoculated with influenza virus and monitored in hospital for 10 days as they develop and get better from flu. Continuously-monitoring wearable physiological sensors will be given to the participants 7 days before this and worn continuously until the end of the flu infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartFeb 11, 2020
Primary CompletionDec 31, 2020
Study CompletionMay 17, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.5 years ago

Interventions

Lumee Oxygen Platformdevice

Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.